MDxHealth SA
mdxhealth.comWhat Do They Do?
Provides molecular diagnostic tests that help urologists assess prostate cancer and urinary tract infections and guide decisions about biopsy and treatment.
20-F for FY2025, filed Apr 3, 2026We are a commercial-stage precision diagnostics company providing non-invasive, clinically actionable and cost-effective urologic solutions…View ↗
Our Exo mdx test — which is a noninvasive (no digital rectal exam (“DRE”) required) urine test with 91% Negative Predictive Value (“NPV”)…View ↗
Upon diagnosis of localized prostate cancer, our GPS mdx test — which measures the expression of a panel of genes in prostate cancer tissue…View ↗
To further supplement our prostate cancer menu, with Resolve mdx we have developed a novel, advanced urinary tract infection (“UTI”) test…View ↗
Who Are Their Customers?
Urologists and their clinical teams order tests, while pathology and laboratory staff fulfill requests for clinician clients. A direct sales force markets the tests to urology practices, and the company also works with pathology laboratories serving urology clients.
20-F for FY2025, filed Apr 3, 2026Our sales team is trained to address the clinical, economic and reimbursement questions associated with selling our tests. Our sales force…View ↗
Strong Commercial Focus and Presence. We aim to increase adoption of our commercial tests by leveraging our direct sales force in the…View ↗
Successful penetration of the urology market and clinical adoption of our tests has been achieved with a multi-faceted approach to build…View ↗
Do Revenues Turn Into Profits?
No. It lost $33.5M in .
20-F for FY2025, filed Apr 3, 2026
How Are They Changing?
Urine test portfolio
The earlier report featured Select mdx for men being considered for a first biopsy; the latest describes Exo mdx as its urine test and says Select mdx customers were transitioned to it.
20-F for FY2022, filed Apr 25, 2023 20-F for FY2025, filed Apr 3, 2026
Loading...
